
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie has demonstrated a robust financial outlook, with management revising global sales guidance for its neuroscience segment to approximately $10.7 billion for 2025, reflecting strong performance across several key products including Vyalev, Vraylar, and Botox Therapeutic. Additionally, the upward revisions in mid-term growth rate estimates for Skyrizi and Rinvoq indicate a positive trajectory in AbbVie's immunology franchise, reinforcing confidence in its future revenue streams. Furthermore, significant global sales growth observed in 3Q25 across several products, combined with the strategic acquisitions of Cerevel and ImmunoGen, enhances AbbVie's potential to sustain and drive its market position in both neurology and oncology sectors.
Bears say
The financial outlook for AbbVie appears negative due to lowered mid-term sales estimates for its aesthetics franchise, particularly concerning Botox and fillers, which have experienced ongoing pressure. Risks include potential shortcomings in commercial execution for significant assets like Skyrizi and Rinvoq, along with clinical setbacks that could hinder growth opportunities for marketed products. Additionally, looming exclusivity loss for Vraylar in 2030 and ongoing macroeconomic pressures that could affect discretionary spending further compound concerns regarding AbbVie's revenue trajectory.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares